Walgreens and Prothena partner to increase access and enrollment in Alzheimer’s disease clinical trial
Late-stage clinical biotechnology company Prothena has engaged Walgreens for its patient identification and recruitment of its ongoing ASCENT-2 multiple ascending dose clinical trial evaluating the safety and tolerability of PRX012, a potential anti-amyloid beta antibody under development for the treatment of Alzheimer’s disease. PRX012 has been granted Fast Track designation by the FDA.
Ramita Tandon, chief clinical trials officer, Walgreens said in a press release, “Through Walgreens trusted community pharmacy presence and daily interactions with millions of patients across America, we believe we can have a meaningful impact in helping Prothena with their clinical trial recruitment efforts. Our aim is to help build a more representative patient population for Alzheimer’s research, particularly among underserved and diverse communities, to create a better understanding of this disease.”
Using Walgreens pharmacy and patient-authorized clinical data, the company will identify and engage with potentially eligible patients and their caregivers to educate them on Prothena’s ASCENT-2 clinical trial. Walgreens will then invite interested patients or their caregivers to complete a pre-screen to determine eligibility for participation at one of Prothena’s clinical trial sites.
Prothena’s Phase I PRX012 single ascending dose (SAD) and multiple ascending dose (MAD) studies are ongoing with topline data expected year end 2023.
Reference: Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial. DEERFIELD, Ill. & DUBLIN--BUSINESS WIRE.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.